What Happened?
Shares of healthcare solutions company Evolent Health (NYSE: EVH) jumped 20.7% in the afternoon session after the company reported fourth-quarter earnings that beat expectations and provided an optimistic revenue forecast for the upcoming year.
The healthcare solutions company announced non-GAAP earnings of $0.08 per share, a significant improvement from the $0.02 per share loss recorded in the same quarter a year earlier and well ahead of analyst forecasts. While quarterly revenue fell 27.5% year-over-year to $468.7 million, this figure met Wall Street's expectations. Investors appeared to focus on the company's strong future guidance. Evolent projected its revenue for the full year 2026 to be between $2.4 billion and $2.6 billion. The midpoint of this range suggested growth of approximately 30% and was nearly 5% above analysts' estimates. The positive outlook seemed to overshadow the company’s lower-than-expected guidance for adjusted EBITDA.
Is now the time to buy Evolent Health? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Evolent Health’s shares are extremely volatile and have had 46 moves greater than 5% over the last year. But moves this big are rare even for Evolent Health and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 12 days ago when the stock gained 3.6% on the news that a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a key measure of inflation, rose by 0.2%, which was less than economists had forecast, with the annual rate cooling to 2.4%. This encouraging data increased market expectations for the Fed to begin cutting interest rates as early as June. The news prompted a rally in Treasuries as their yields fell. While the market's reaction was initially described as a "bumpy ride" due to concerns in other sectors, the favorable inflation data ultimately helped calm Wall Street. Lower inflation is a key prerequisite for the central bank to ease its monetary policy, which is generally supportive of stock valuations.
Evolent Health is down 19.2% since the beginning of the year, and at $3.15 per share, it is trading 73.3% below its 52-week high of $11.79 from July 2025. Investors who bought $1,000 worth of Evolent Health’s shares 5 years ago would now be looking at an investment worth $160.21.
Microsoft, Alphabet, Coca-Cola, Monster Beverage—all began as under-the-radar growth stories riding a massive trend. We’ve identified the next one: a profitable AI semiconductor play Wall Street is still overlooking.Go here for access to our full report, it’s free.
